iRemedy says 89% of essential medicines show Chinese supply chain dependency

By AI, Created 2:00 PM UTC, May 20, 2026, /AGP/ – iRemedy Healthcare Companies released an AI-powered assessment of all 84 medicines on the federal ASPR Essential Medicines List, saying 75 show significant dependency on China at one or more supply chain tiers. The report is meant to give federal buyers, hospitals, and policymakers a medicine-by-medicine view of foreign exposure in U.S. drug supply chains.

Why it matters: - iRemedy’s assessment targets medicines the federal government treats as essential, making supply chain exposure a patient care and national security issue. - The report lands as lawmakers and regulators intensify scrutiny of drug shortages and pharmaceutical dependence on China. - iRemedy says the analysis is intended to help federal procurement officers and healthcare buyers identify hidden supply risk before shortages hit.

What happened: - iRemedy Healthcare Companies released the Foreign Dependency Assessment on May 20, 2026. - The analysis covers all 84 medicines on the ASPR Essential Medicines List. - TheTradeSpy.ai, iRemedy’s autonomous supply chain intelligence platform, produced the assessment. - iRemedy says 75 of the 84 medicines, or 89.3%, show significant dependency on China at one or more supply chain tiers. - The full report is available here.

The details: - The assessment traces each medicine through four layers of dependency verification: direct U.S. import flows, supplier-country import flows, key starting material precursor flows, and peer-reviewed literature attribution. - iRemedy says country-of-origin labels often do not reflect the ultimate source of active pharmaceutical ingredients or key starting materials. - The report says Norway, Portugal, Morocco, Mexico, and India often appear as U.S. suppliers but function mainly as last-step processors of material that originated elsewhere. - The analysis identifies 31 of the 84 essential medicines with at least one U.S.-marketed product linked to a Chinese state-affiliated manufacturer. - iRemedy says standard procurement databases do not always reflect parent-company ownership structures. - The report flags heparin as a case where parent-company ownership linkage creates an actionable data-quality issue for federal procurement authorities. - iRemedy says 85%+ of the nucleus compounds for the beta-lactam antibiotic family, including amoxicillin and ceftriaxone, are attributed to Chinese origin. - The company says 9 of the 84 medicines appear structurally independent of Chinese supply chain dependency. - TheTradeSpy.ai uses 31 AI agents across more than 129,000 National Drug Codes. - The platform synthesizes bills of lading, UN Comtrade data, FDA regulatory filings, and corporate ownership records. - The system uses a deterministic 63-factor model to generate a Made-in-America confidence score at the NDC level. - iRemedy says all percentages are conservative lower-bound estimates by physical weight. - The company says every determination carries its source, timestamp, and confidence tier.

Between the lines: - The report argues that finished-product labeling can mask upstream dependence, which makes the issue harder to see in ordinary procurement workflows. - By tying supply exposure to ownership records and precursor materials, iRemedy is pushing the debate beyond country-of-label toward country-of-origin in the chemical chain. - The company is also framing the issue as a data integrity problem, not just a sourcing problem. - Tony Paquin, iRemedy’s founder and CEO, said the findings show fraud and hidden ownership structures, and he said the goal is to make the true origin of medicine supply visible, measurable, and actionable.

What’s next: - iRemedy says the assessment is available for federal agencies, healthcare systems, and qualified strategic partners through TheTradeSpy.ai. - The company is positioning the platform as a procurement tool for buyers that want to screen suppliers and reduce exposure to foreign dependency. - iRemedy says the report will support ongoing efforts to strengthen medicine supply chain security and shortage preparedness.

The bottom line: - iRemedy’s new AI analysis says Chinese dependency reaches deep into U.S. essential medicines, and that the risk is often hidden behind finished-product labels and layered supply chains.